

TETRAHEDRON LETTERS

Efficient route to optically pure polyfunctionalized cyclooctanes

Christine Gravier-Pelletier, Olivia Andriuzzi and Yves Le Merrer*

Universite´ Rene´ Descartes, *Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques*, *UMR* 8601 *CNRS*, 45, *rue des Saints*-*Pe`res*, 75270 *Paris Cedex* 06, *France*

Received 28 September 2001; accepted 8 November 2001

Abstract—A short and efficient synthesis of enantiopure highly functionalized eight-membered carbocyclic rings is described from 1,2:5,6-bis-epoxides issued from D-mannitol. The key cyclization step involves the metathesis of 1,9-diene using Grubbs' catalyst or the pinacolic coupling of 1,8-dialdehyde resulting from the oxidative cleavage of the previous diene. In the specific case of ring-closing metathesis cyclization, the influence of a conformationally restricted diene compared to that of a flexible one has been evaluated. © 2002 Elsevier Science Ltd. All rights reserved.

The conversion of carbohydrate derivatives into carbasugars, sugars for which the endocyclic oxygen atom has been replaced by a methylene group, is well documented for the $C5$ and $C6$ series¹ and this has given rise to interesting biologically active compounds such as trehazolamines, conduritols or inositols. However, only a few approaches have been dedicated to analogous routes in the $C⁷²$ and $C⁸³$ series. In the latter case, the unfavorable thermodynamic factors are claimed to limit the access to C8 cyclitols.4

As part of our ongoing research on the synthesis of new glycosidases inhibitors and especially on the synthesis of new potential drugs to treat non-insulino-dependant (NID) diabetes, we considered the structure of either voglibose itself or valienamine as an essential core unit of acarbose (Fig. 1).

Both voglibose⁵ and acarbose⁶ display powerful α -Dglucosidase inhibition and have already found therapeutic application in NID diabetes. In this context, our goal was to develop a straightforward and efficient route to cyclooctanic carbasugar analogs in order to study the effect of an increase in the flexibility of the resulting targets on the expected enhanced adaptability of cyclooctanic structure within the active site of the enzyme. Furthermore, the availability of various configurations of the carbasugar should enable us to examine the consequence of different distributions of the hydroxyl groups on the activity.

* Corresponding author. Tel.: $+33(0)142862176$; fax: +33(0)142868387; e-mail: yves.le-merrer@biomedicale.univ-paris5.fr

Figure 1. Examples of non-insulino-dependant diabetes therapeutic agents.

Our retrosynthetic analysis (Scheme 1) involves two different pathways, namely the carbocyclization of enantiomerically pure 1,9-diene and the carbocyclization of 1,8-dialdehyde which results from oxidative cleavage of the previous diene. The key step requires either an intramolecular cycloaddition by ring-closing metathesis (RCM) or a pinacolic coupling (PC). The synthetic route begins with C2-symmetrical bis-epoxides easily available from D-mannitol.

Although ring-closing metathesis has been largely used in the synthesis of heterocyclic compounds⁷ and in that of C5 to C7 cyclitols,^{1a,1c,1e,2a,2b} only a few examples deal with the obtention of C8 cyclitols^{3a,3b} and the recent work published in this field^{3b,3d} has prompted us to submit our results.8 First, the regiospecific opening of C2 symmetrical L-*ido* bis-epoxide **2**, readily available from D -mannitol,⁹ by an excess of lithium divinyl

Keywords: cycloctane; metathesis; 1,9-diene; 1,8-dialdehyde; pinacolic coupling; Grubbs' catalyst.

⁰⁰⁴⁰⁻⁴⁰³⁹/02/\$ - see front matter © 2002 Elsevier Science Ltd. All rights reserved. PII: $S0040 - 4039(01)02126 - 8$

Scheme 1. Retrosynthetic analysis.

cyanocuprate¹⁰ was carried out at −78°C to cleanly afford the diene 3 in 90% yield¹¹ (Scheme 2). The carbocyclization involving Grubbs' commercially available ruthenium catalyst $[(PCy₃),Cl₂Ru=CHPh, up to 13]$ mol%], 0.005 M in CH₂Cl₂ at 20 \degree C for 96 h, efficiently gave the expected cyclooctene **4** in 87% yield. The simplicity of both the ¹H and ¹³C NMR spectra of 4¹² revealed the retention of the C2-axis of symmetry and showed the formation of the thermodynamically more stable *cis*-cyclooctene. It is worthy of note that, in our case, RCM led to the cyclized product at 20°C without requiring the protection of the two hydroxyl groups of the diol 3^{13}

Both hydroxyl groups were then protected as their *tert*-butyldimethylsilyl ethers **5** (TBDMSCl, imidazole, DMF) prior to exploring the synthetic potentialities at the newly created double bond of this enantiomerically pure polyhydroxycyclooctenic structure (Scheme 3). syn -Dihydroxylation¹⁴ by a 5 mol% aqueous solution of osmium tetroxide, in dichloromethane, in the presence of *N*-methylmorpholine oxide and *tert*-butanol afforded the enantiopure polyhydroxylated cyclooctane derivative **6a** in 97% yield. Alternatively, the epoxidation of the double bond¹⁵ in the presence of *meta*chloroperbenzoic acid and sodium hydrogenocarbonate cleanly gave the enantiopure epoxide **7** in 92% yield.

We next turned to the second proposed pathway involving the pinacolic coupling of 1,8-dialdehyde. For that purpose (Scheme 4), the secondary alcohol functions of the diol **3** were protected as their *tert*butyldimethylsilyl ethers (TBDMSCl, imidazole, DMF) to give the entirely protected compound **8**. Ozonolysis of both double bonds of **8** in dichloromethane and methanol followed by the decomposition of the resulting ozonide by trimethylphosphite, furnished the expected dialdehyde **9** in 70% yield. Reductive coupling was then carried out by samarium diiodide (0.1 M in THF) in the presence of *tert*-butanol and HMPA¹⁶ to promote the cyclization. In these conditions, efficient cyclization occurred affording the cyclooctanediol skeleton in 62% yield as a 1:1 diastereomeric mixture of *cis* and *trans* cycloadducts **6a** and **6b**. ¹⁷ The *cis* relation

Scheme 2.

Scheme 3.

Scheme 4.

ship in **6a** has been shown by comparison with the same compound previously obtained by *syn*-dihydroxylation of the cyclooctene **5** resulting from RCM.

Due to the poor observed diastereoselectivity of pinacolic coupling cyclization, it is obvious that RCM followed by *syn*-dihydroxylation or *syn*-epoxidation was a better method to reach the targeted compounds. So, we proceeded to the generalization of the RCM to other substrates displaying different configuration and/ or higher flexibility of the backbone in order to test the presumed entropic assistance to the cyclization process of the acetonide moiety in the conformationally restricted diene **3** (Scheme 5). To this end, both D*manno*-1,9-dienes **12** and **13** were prepared from the corresponding D-manno-bis-epoxides^{9,18} according to the same conditions as the diene **3**. As for the L-*ido*-acetonide diene **3**, the D-*manno*-acetonide diene **12** was isolated in good yield (80%). However, our previous work¹⁹ has shown that bis-opening of flexible di- O -benzyl-bis-epoxide by a nucleophile is competitive with *O*-cyclization involving the alcoholate resulting from the nucleophilic opening of a single epoxide moiety. Nevertheless, the low temperature of the reaction (−78°C) allowed us to minimize the *O*-cyclization and the expected diene **13** was isolated in 30% yield. To our great satisfaction, RCM of both dienes **12** and **13**, in the same conditions as above, efficiently afforded the corresponding cycloadducts **14**¹² and **15**¹² in 65 and 50% non-optimized isolated yield.

In summary, RCM was a powerful method to reach polyhydroxycyclooctene structures displaying diverse configurations and allowing various, either rigid or flexible, protective groups for the central diol. In this study, protection of hydroxyl groups at homoallylic positions proved to be unnecessary since the RCM occurred in good to excellent yield. Furthermore, *syn*diol or *syn*-epoxide resulting from dihydroxylation or epoxidation of cyclooctenic structure may be considered as key intermediates in the obtention of the targeted C8-amino cyclitols. Work on the synthesis of voglibose mimics is now in progress and will be reported in due course.

Acknowledgements

We thank James McCabe (Centre for Technical Languages, Université René Descartes, Paris 5) for his critical reading of this manuscript.

References

- 1. For example, see: (a) Ackermann, L.; El Tom, D.; Fürstner, A. *Tetrahedron* **2000**, 56, 2195–2202; (b) Kan, T.; Nara, S.; Ozawa, T.; Shirahama, H.; Matsuda, F. *Angew*. *Chem*., *Int*. *Ed*. **2000**, 39, 355–357; (c) Callam, C. S.; Lowary, T. L. *Org*. *Lett*. **2000**, ², 167–169; (d) Carpintero, M.; Jaramillo, C.; Fernandes-Mayoralas, A. *Eur*. *J*. *Org*. *Chem*. **2000**, 1285–1296; (e) Sellier, O.; Van de Weghe, P.; Eustache, J. *Tetrahedron Lett*. **1999**, 40, 5859– 5860.
- 2. (a) Boyer, F.-D.; Hanna, I. *Tetrahedron Lett*. **2001**, ⁴², 1275–1277; (b) Marco-Contelles, J.; de Opazo, E. *Tetrahedron Lett*. **2000**, 41, 2439–2441; (c) Marco-Contelles, J.; de Opazo, E. *J*. *Org*. *Chem*. **2000**, 65, 5416–5419.
- 3. (a) Hanna, I.; Ricard, L. *Org*. *Lett*. **2000**, ², 2651–2654; (b) Boyer, F.-D.; Hanna, I.; Nolan, S. P. *J*. *Org*. *Chem*. **2001**, 66, 4094–4096 and references cited therein; (c) Wang, W.; Zhang, Y.; Sollogoub, M.; Sinaÿ, P. Angew. *Chem*., *Int*. *Ed*. **2000**, 39, 2466–2467; (d) McNulty, J.; Grunner, V.; Mao, J. *Tetrahedron Lett*. **2001**, ⁴², 5609– 5612.
- 4. Miller, S. J.; Kim, S.-H.; Chen, Z.-R.; Grubbs, R. H. *J*. *Am*. *Chem*. *Soc*. **1995**, 117, 2108–2109.
- 5. Hirose, T.; Miyashita, Y.; Takagi, M.; Sumitani, S.; Kouhara, H.; Kasayama, S. *Diabetes Res*. *Clin*. *Pract*. **2001**, 54, 9–15.
- 6. Cornish, W. R. *Can*. *J*. *Clin*. *Pharmacol*. **1997**, ⁴, 15–23.
- 7. For example, see: Phillips, A. J.; Abell, A. D. *Aldrichim*. *Acta* **1999**, 32, 75–88.
- 8. A part of this work was previously presented as a poster: Gravier-Pelletier, C.; Andriuzzi, O.; Le Merrer, Y. Polyfunctionalized Cyclooctanes as carbohydrate mimics or scaffolds. *De la conception à la réalisation en pharmacochimie*, Proceedings of the XVEME Journées Franco-Belges de Pharmacochimie, Namur (Belgium), May 31st–June 1st, 2001.
- 9. (a) Le Merrer, Y.; Duréault, A.; Greck, C.; Micas-Languin, D.; Gravier, C.; Depezay, J. C. *Heterocycles* **1987**, 25, 541–548; (b) Vargha, L.; Kasztreiner, E. *Chem*. *Ber*. **1959**, 2506–2515.
- 10. For an analogous reaction on D-*manno*-bis-epoxide, see: Sanière, M.; Le Merrer, Y.; Barbe, B.; Koscielniak, T.; Micas-Languin, D.; Dumas, J.; Depezay, J. C. *Angew*. *Chem*., *Int*. *Ed*. **1989**, 28, 614–616.
- 11. All new compounds were characterized by analytical and spectroscopic data. Yields are given for isolated, chromatographically purified products.
- 12. Selected physical data for **4**, **14** and **15**:**4**: ¹ H NMR (250 MHz, CDCl₃, δ ppm): 5.78–5.73 (m, 2H, H_{1,8}), 3.83–3.74 $(m, 2H, H_{3,6}),$ 3.70–3.58 $(m, 2H, H_{4,5}),$ 2.46–2.24 $(m, 4H,$ $H_{2,2,7,7}$, 1.35 (s, 6H, Me), the following coupling constants can be found by proton selective irradiations $J_{2,2} \approx$ 13.9 Hz, *J*_{1,2} = 3.5 Hz, *J*_{1,2} = 6.8 Hz. ¹³C NMR (62.5 MHz, CDCl₃, δ ppm): 127.7 (C_{1,8}), 108.9 (CMe₂), 82.2, 72.5 (C_{3,4,5,6}), 30.3 (C_{2,7}), 26.8 (CMe₂). **14**: ¹H NMR (250 MHz, CDCl₃, δ ppm) 5.81–5.67 (m, 2H, H_{1,8}), 4.23 (s, 2H, H_{4,5}), 4.19–4.11 (m, 2H, H_{3,6}), 2.50–2.31 (m, 4H, $H_{2,2',7,7'}$), 1.42 (s, 6H, Me). ¹³C NMR (62.5 MHz, CDCl₃, δ ppm): 128.0 (C_{1,8}), 108.2 (CMe₂), 77.0, 67.5 (C_{3,4,5,6}), 29.0 (C_{2,7}), 27.2 (CMe₂). **15**: ¹H NMR (250 MHz, CDCl₃, δ ppm) 7.36–7.26 (m, 10H, Ph), 5.70–5.60 (m, 2H, H_{1,8}), **Scheme 5.** 4.85 (AB, 2H, *J*_{A,B}=11.4 Hz, CH₂Bn), 4.53 (A^{'B'}, 2H,

 $J_{A,B}$ =11.4 Hz, CH₂Bn), 4.21–4.13 (m, 2H, H_{4,5}), 3.91 $(m, 2H, H_{3,6}), 2.38-2.30$ $(m, 4H, H_{2,2',7,7}).$ ¹³C NMR $(62.5 \text{ MHz}, \text{CDCl}_3, \delta \text{ ppm})$: 128.5, 128.3, 127.9 (C_{Ar}), 127.6, $(C_{1,8})$, 74.2 (PhCH₂), 78.3, 71.0 $(C_{3,4,5,6})$, 29.7 $(C_{2,7})$.

- 13. For the effect of hydroxyl groups in RCM reactions, see: Hoyes, T. R.; Zhao, H. *Org*. *Lett*. **1999**, 1, 1123–1125.
- 14. Mehta, G.; Ramesh, S. S. *Chem*. *Commun*. **2000**, 2429– 2430.
- 15. Barrett, S.; O'Brien, P.; Steffens, H. C.; Towers, T. D.;

Voith, M. *Tetrahedron* **2000**, 56, 9633–9640.

- 16. Riber, D.; Hazell, R.; Skrydstrup, T. *J*. *Org*. *Chem*. **2000**, 65, 5382–5390.
- 17. The proportion of the two possible *trans* derivatives **6b** has not been determined.
- 18. For the preparation of 1,2:5,6-dianhydro-3,4-di-*O*-benzyl-D-mannitol, see: Poitout, L.; Le Merrer, Y.; Depezay, J. C. *Tetrahedron Lett*. **1994**, 35, 3293–3296.
- 19. Poitout, L.; Le Merrer, Y.; Depezay, J. C. *Tetrahedron Lett*. **1995**, 36, 6887–6890.